logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Feb 2023
Apellis Pharmaceuticals, Inc.
Top-line 48-week data from phase III PEGASUS trial of EMPAVELI (pegcetacoplan)
Paroxysmal nocturnal hemoglobinuria
1H 2023
FibroGen Inc.
Topline data from the LELANTOS-1 Phase 3 study of Pamrevlumab
Non-ambulatory Duchenne Muscular Dystrophy (DMD)
1H 2023
FibroGen Inc.
Topline data from the MATTERHORN Phase 3 study of Roxadustat
Anemia Associated with Myelodysplastic Syndromes (MDS)
2023
REVOLUTION MEDICINES, INC.
Data from Phase 1/1b monotherapy trial of RMC-6236
Solid tumors
2023
REVOLUTION MEDICINES, INC.
Data from Phase 1/1b monotherapy trial of RMC-6291
KRASG12C-mutant solid tumors
1H 2023
Aclaris Therapeutics
Topline data from phase IIa trial of Zunsemetinib
Hidradenitis Suppurativa
1H 2023
Aclaris Therapeutics
Topline results from Phase IIb trial of ATI-1777
Atopic Dermatitis
2023
ADC Therapeutics
Preliminary safety and tolerability data from phase I trial of ADCT-901
Solid tumors
2023
Alector Inc.
Follow-up data from the INFRONT-2 Phase 2 clinical trial of Latozinemab
Frontotemporal dementia
1H 2023
Regeneron Pharmaceuticals
Topline results from Phase 3 study of Dupixent (Dupilumab)
Chronic Inducible Cold Urticaria
1H 2023
Regeneron Pharmaceuticals
Topline results from Phase 3 study of Dupixent (Dupilumab)
Chronic Obstructive Pulmonary Disease
1H 2023
Replimune Group Inc.
Topline primary analysis data from CERPASS phass II clinical trial evaluating RP1 combined with Libtayo
Cutaneous Squamous Cell Carcinoma (CSCC)
1H 2023
Replimune Group Inc.
Data from cohorts of patients with anti-PD1 failed non-melanoma skin cancers,
Non-melanoma Skin Cancer
1H 2023
Replimune Group Inc.
Data from ARTACUS phase Ib/II solid organ transplant trial of RP1 monotherapy
Cutaneous Malignancies
1H 2023
SpringWorks Therapeutics
Data from Phase 2b ReNeu trial evaluating Mirdametinib
NF1-associated plexiform neurofibromas (NF1-PN)
1H 2023
SpringWorks Therapeutics
Data from Phase 1b/2 trial evaluating Mirdametinib with BeiGene’s RAF dimer inhibitor, Lifirafenib
Metastatic Solid Tumors
1H 2023
ASSEMBLY BIOSCIENCES, INC.
Complete data from Phase 1b trial of ABI-H3733
Chronic Hepatitis B
1H 2023
ASSEMBLY BIOSCIENCES, INC.
Complete data from Phase 1a trial of ABI-4334
Chronic Hepatitis B
1H 2023
Baudax Bio, Inc
Interim data from Phase II trial of BX 1000
Neuromuscular blocade for surgical settings
1H 2023
Cerevel Therapeutics Holdings Inc.
Data from EMPOWER-2 Phase 2 trial of Emraclidine
Schizophrenia
1H 2023
Inovio Pharmaceuticals Inc.
Results from the second cohort of Phase 1/2 trial of INO-3107
Recurrent Respiratory Papillomatosis (RRP)
1H 2023
Shattuck Labs, Inc
Initial data from Phase 1A/B Clinical Trial of in SL-172154
Acute Myeloid Leukemia
Q1 2023
Shattuck Labs, Inc
Top-line data from the Phase 1 Dose-Escalation Clinical Trial of SL-279252
Advanced Solid Tumor
1H 2023
Taysha Gene Therapies, Inc.
Preliminary data from first cohort of adult patients of Phase 1/2 trial of TSHA-102
Rett syndrome
Late Q1 2023
Vaxart, Inc.
Topline data from Phase II norovirus challenge study of VXA-NVV-104
Norovirus